Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1980076 | 0.87 | NOTUM (0.56) | NOTUMMAPTCA1CA2CA12 | |
| SCHEMBL2297062 | 0.86 | NOTUM (0.51) | NOTUMMAPTCA1CA2CA12 | |
| SCHEMBL24425908 | 0.83 | MAPT (0.50) | NOTUMMAPTCA1CA2CA12 | |
| SCHEMBL977072 | 0.83 | KMT2A (0.53) | CA1CA2CA12CA7CA9 | |
| SCHEMBL426745 | 0.83 | MAPT (0.62) | NOTUMMAPTCA1CA2CA12 | |
| SCHEMBL6568018 | 0.82 | MAPT (0.66) | MAPTCA1CA2CA12CA7 | |
| SCHEMBL28663604 | 0.82 | MAPT (0.66) | MAPTCA1CA2CA12CA7 | |
| SCHEMBL2827824 | 0.82 | NOTUM (0.56) | NOTUMMAPTCA1CA2CA12 | |
| SCHEMBL7356100 | 0.81 | MAPT (0.46) | NOTUMMAPTCA1CA2CA12 | |
| SCHEMBL2827834 | 0.81 | ALDH1A1 (0.47) | NOTUMMAPTCA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116102449-A | Phenyl derivatives as cannabinoid receptor 2 agonists | 豪夫迈·罗氏有限公司 | 2023-05-12 | — | — | CN | disclosed |
| US-11572374-B2 | N-cyano-7-azanorbornane derivatives and uses thereof | AMGEN INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220363694-A1 | N-CYANO-7-AZANORBORNANE DERIVATIVES AND USES THEREOF | AMGEN INC. (US) | 2022-11-17 | — | — | US | disclosed |
| CN-108349901-B | Phenyl derivatives as cannabinoid receptor 2 agonists | 豪夫迈·罗氏有限公司 | 2022-08-16 | — | — | CN | disclosed |
| US-11339120-B2 | Phenyl derivatives as cannabinoid receptor 2 agonists | HOFFMANN-LA ROCHE INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339120-B2 | Phenyl derivatives as cannabinoid receptor 2 agonists | HOFFMANN-LA ROCHE INC. (US) | 2022-05-24 | — | — | US | disclosed |
| EP-3837262-A1 | N-CYANO-7-AZANORBORNANE DERIVATIVES AND USES THEREOF | Amgen Inc. (US) | 2021-06-23 | — | — | EP | disclosed |
| CN-112979630-A | Trifluoromethanols as Ror gamma t modulators | 詹森药业有限公司 | 2021-06-18 | — | — | CN | disclosed |
| US-20210171441-A1 | PHENYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-20210171441-A1 | PHENYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | US | disclosed |
| WO-2009064250-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 065 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064250-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 065 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064251-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064251-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171441-A1 | PHENYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | CNR2, CNR1, GPR18 | NOTUM 2223/4885MAPT 1838/4885CA1 4579/4885 |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | PTGER1, CYP3A5, SULT1E1 | NOTUM 374/4885MAPT 981/4885CA1 3705/4885 |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | CYP2D6, PTGER1, CYP2B6 | NOTUM 649/4885MAPT 1161/4885CA1 3657/4885 |
| US-11572374-B2 | N-cyano-7-azanorbornane derivatives and uses thereof | CYP3A7, CYP51A1, NT5C3B | NOTUM 473/4885MAPT 4708/4885CA1 2410/4885 |
| US-11339120-B2 | Phenyl derivatives as cannabinoid receptor 2 agonists | CNR2, CNR1, GPR18 | NOTUM 2223/4885MAPT 1838/4885CA1 4579/4885 |
| US-20220363694-A1 | N-CYANO-7-AZANORBORNANE DERIVATIVES AND USES THEREOF | CYP3A7, CYP51A1, NT5C3B | NOTUM 473/4885MAPT 4708/4885CA1 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.